Clinical TrialMay 14, 2026, 06:02 AM
Editas Medicine's EDIT-401 Shows Durable LDL-C Reduction in Preclinical Data
AI Summary
Editas Medicine shared new preclinical data for its lead in vivo development candidate, EDIT-401, supporting its potential as a one-time treatment for hyperlipidemia. The data, presented at ASGCT and TIDES USA 2026, demonstrated a rapid and durable ">=90%" mean LDL-C reduction in non-human primates for "~6 months" with a promising safety profile. These findings strengthen confidence in EDIT-401's advancement toward first-in-human clinical development and highlight the broader potential of the Company's upregulation strategy.
Key Highlights
- Single dose of EDIT-401 achieved ">=90%" mean LDL-C reduction across all dose groups in non-human primates (NHPs).
- LDL-C lowering was rapid and durable for "~6 months" across evaluated dose levels (1.5 mg/kg-3.0 mg/kg).
- Promising preclinical safety profile with no adverse clinical observations at therapeutically relevant dose (1.5 mg/kg).
- Achieved ">=90%" mean LDL-C reduction with "10-40%" functional editing of LDLR alleles and ">=6-fold" mean increase in hepatic LDLR protein.
- Highest delivery of EDIT-401 was observed in hepatocytes compared to other non-target tissues, with undetectable oocyte delivery.
- Data suggests dose adjustments may not be needed to achieve LDL-C lowering in Heterozygous Familial Hypercholesterolemia (HeFH) patients.
Price Impact
More from EDIT